Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
- PMID: 32061595
- DOI: 10.1053/j.gastro.2020.01.052
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic steatohepatitis, affect 30% and 5% of the population, respectively. Considering the ongoing obesity epidemic beginning in childhood, the rise in diabetes, and other factors, the prevalence of NAFLD along with the proportion of those with advanced liver disease is projected to continue to increase. This will have an important impact on public health reflected in health care costs, including impact on the need for liver transplantation, for which nonalcoholic steatohepatitis is already close to becoming the most common indication. NAFLD patients with evidence of nonalcoholic steatohepatitis and advanced fibrosis are at markedly increased risk of adverse outcomes, including overall mortality, and liver-specific morbidity and mortality, respectively. Identification of this cohort of NAFLD patients is paramount, given the associated poorer outcomes, in order to target resources to those who need it most. Various noninvasive tools have been developed in this regard. This review provides an update on the epidemiology, clinical and prognostic features, and diagnostic approach to patients with NAFLD.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263. World J Gastroenterol. 2017. PMID: 29307986 Free PMC article. Review.
-
Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.Semin Liver Dis. 2015 Aug;35(3):221-35. doi: 10.1055/s-0035-1562943. Epub 2015 Sep 17. Semin Liver Dis. 2015. PMID: 26378640 Review.
-
Nonalcoholic fatty liver disease as a multi-systemic disease.World J Gastroenterol. 2016 Apr 28;22(16):4079-90. doi: 10.3748/wjg.v22.i16.4079. World J Gastroenterol. 2016. PMID: 27122660 Free PMC article. Review.
-
Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.Transplantation. 2019 Jan;103(1):22-27. doi: 10.1097/TP.0000000000002484. Transplantation. 2019. PMID: 30335697 Review.
-
Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.World J Gastroenterol. 2019 Mar 21;25(11):1307-1326. doi: 10.3748/wjg.v25.i11.1307. World J Gastroenterol. 2019. PMID: 30918425 Free PMC article. Review.
Cited by
-
Advancing non-alcoholic fatty liver disease prediction: a comprehensive machine learning approach integrating SHAP interpretability and multi-cohort validation.Front Endocrinol (Lausanne). 2024 Oct 8;15:1450317. doi: 10.3389/fendo.2024.1450317. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39439566 Free PMC article.
-
Saccharomyces boulardii Mitigates Fructose-Induced Non-Alcoholic Fatty Liver in Rats.Medicina (Kaunas). 2024 Oct 18;60(10):1713. doi: 10.3390/medicina60101713. Medicina (Kaunas). 2024. PMID: 39459500 Free PMC article.
-
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management.Adv Ther. 2021 May;38(5):2130-2158. doi: 10.1007/s12325-021-01690-1. Epub 2021 Apr 7. Adv Ther. 2021. PMID: 33829368 Free PMC article. Review.
-
RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression.Cell Biosci. 2022 Oct 12;12(1):172. doi: 10.1186/s13578-022-00910-7. Cell Biosci. 2022. PMID: 36224648 Free PMC article.
-
The evolving view of thermogenic fat and its implications in cancer and metabolic diseases.Signal Transduct Target Ther. 2022 Sep 16;7(1):324. doi: 10.1038/s41392-022-01178-6. Signal Transduct Target Ther. 2022. PMID: 36114195 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical